NCT02082652View on ClinicalTrials.gov

A Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Antiretroviral Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
HIVContraception
Interventions
DRUG

Etonogestrel

Etonogestrel single-rod subdermal implant (68mg/rod) is placed upon enrollment (day 0) and remains in place until participant requests removal or for the duration of active drug (currently approved for 3 years of use).

Trial Locations (1)

Unknown

Infectious Disease Institute, Kampala

All Listed Sponsors
collaborator

Makerere University

OTHER

lead

University of Pittsburgh

OTHER

NCT02082652 - A Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Antiretroviral Therapy | Biotech Hunter | Biotech Hunter